Innovative Medicines Initiative

What Innovative Medicines Initiative does

Innovative Health Initiative (IHI), formerly the Innovative Medicines Initiative (IMI), is an EU public-private partnership founded in 2008 and rebranded in 2021 to reflect an expanded scope across pharmaceuticals, biotechnology, medical technology, and big data. Headquartered in Belgium with 1,001-5,000 employees, IHI operates as a joint undertaking between the European Commission and five core contributing industry associations — COCIR, EFPIA, EuropaBio, MedTech Europe, and Vaccines Europe — to fund collaborative health research and innovation projects. Its core activity is the administration of competitive funding calls; for example, Call 13 allocated €84.8 million across workstreams on immune diseases in the elderly, a health innovator network, and 3Rs (Replace, Reduce, Refine) animal-research practices.

The organisation does not sell products or services in the traditional sense; instead, it functions as a funding intermediary and convening platform. Applicants — academic consortia, SMEs, hospitals, and large industry players — access funding through open and closed calls, contribute their own resources, and use IHI's partner-finding tools, regulatory engagement resources, and open science infrastructure. IHI's revenue model is effectively a public-private partnership budget funded by EU Horizon Europe contributions matched by industry association commitments. Beyond funding distribution, IHI invests in ecosystem building through its annual IHI Forum, monthly newsletters, project factsheets, and dedicated resources for regulatory engagement (notably the ARDAT project advancing gene therapy regulatory science).

Strategically, IHI's value proposition rests on its ability to bring together cross-sector stakeholders — pharmaceutical, biotech, medtech, and data — under a single EU-backed platform that no private entity can replicate. Its leadership team is led by Executive Director Pierre Meulien. Operationally, IHI is in a steady-state phase with continued call cadence, no reported M&A or fundraising activity, and a governance model that ties its fortunes to EU policy cycles and industry association commitments rather than market-based revenue growth.

Name

Innovative Medicines Initiative

Legal name

Innovative Health Initiative

Website

https://imi.europa.eu

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Innovative Health Initiative (IHI) is an EU public-private partnership, founded in 2008, that funds collaborative health research across pharmaceuticals, biotechnology, medical technology, and big data. It serves European academics, SMEs, hospitals, and industry partners through competitive funding calls and a convening platform.

Ownership category

akta.pro rank

Product category

Health Research Funding

NAICS

Scientific Research and Development Services (5417), Voluntary Health Organizations (813212)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Global Health Financing Mechanisms (HLAJAKAC)

akta.pro secondary industries

International & Global Public Health Aid Administration (Government Donors) (HLAJALAO), Global Health Financing Mechanisms & Pooled Funds (HLAJAOAC), Global Health & Population Intergovernmental Bodies (BPADAAAD), Health Systems Strengthening & Global Health Technical Assistance (BPADAEAH)

Keywords

• Health research funding
• Public-private partnership
• Pharmaceutical innovation programs
• Medical research collaboration
• Biomedical research grants

Headquarters

HQ city

Berchem

HQ country

Belgium

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others, Marketing or Sales, Technology or R&D

Revenue model

1. Public-private partnership funding: IHI funds health research and innovation through a public-private partnership model, leveraging contributions from both EU funding and industry partners to support projects addressing public health needs and improving patients' lives.

Distribution channels1 record

Marketing channels4 records

Core offering

IHI is an EU public-private partnership that funds collaborative health research and innovation projects across pharmaceuticals, biotechnology, medical technology, and big data. It allocates funding through competitive calls (e.g., IHI Call 13 with €84.8 million) and supports projects that address public health needs, improve patients' lives, and boost the competitiveness of Europe's health industries.

Product overview

Innovative Health Initiative (IHI) is an EU public-private partnership that funds health research and innovation rather than offering traditional software products. IHI leverages expertise across pharmaceuticals, biotechnology, medical technology, and big data to fund projects addressing public health needs and improving patients' lives. The initiative operates through funding calls (currently IHI Call 13 with €84.8 million for immune diseases in the elderly), project collaboration, and resource provision for the European health industries. No distinct branded products or modules were identified in the provided source data.

Differentiator

Problem solved

Functional benefit

Products and services

• IHI Open Funding Calls for Proposals Competitive funding calls through which organizations (industry and academia) apply to receive co-funding for collaborative health research and innovation projects. Call 13 offered €84.8 million for projects on tackling immune diseases in the elderly, a network for health innovators, and 3Rs research.
• IHI Contributing Partner Program Program enabling industry associations and companies (COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe) to contribute resources and shape upcoming research topics alongside EU funding. Contributing partners gain a role in shaping call topics and participate in collaborative health research initiatives.
• Regulatory Engagement Resources for Funded Projects Resource offering for IHI-funded projects that supports engagement with regulators and regulatory science, exemplified by the ARDAT project's support for gene therapy regulatory pathways.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered core.

• COCIR (European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry)coreStrategic or Co-development PartnerCOCIR is one of IHI's contributing partners representing the European radiolocation, electromedical, and healthcare IT industry. COCIR contributes resources and expertise to IHI's collaborative research projects.
• EFPIA (European Federation of Pharmaceutical Industries and Associations)coreStrategic or Co-development PartnerEFPIA represents pharmaceutical companies across Europe and is a contributing partner to IHI, bringing industry expertise and resources to collaborative health research initiatives.
• EuropaBiocoreStrategic or Co-development PartnerEuropaBio represents the European biotechnology industry and contributes to IHI as a strategic partner, providing biotechnology expertise and resources for collaborative research projects.
• MedTech EuropecoreStrategic or Co-development PartnerMedTech Europe represents the European medical technology industry and is a contributing partner to IHI, bringing medical technology expertise to collaborative health innovation projects.
• Vaccines EuropecoreStrategic or Co-development PartnerVaccines Europe represents vaccine manufacturers in Europe and contributes to IHI as a strategic partner, providing vaccine industry expertise and resources for collaborative research.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• Wellcome Trust: A major charitable foundation funding health research globally, including translational and clinical research. Comparable as a large-scale, non-commercial health research funder with multi-disciplinary scope and convening power.
• Coalition for Epidemic Preparedness Innovations (CEPI): A global public-private partnership that funds and coordinates vaccine development against epidemic threats. Directly comparable to IHI as a multi-stakeholder health R&D financing mechanism with government and industry co-funding.
• Medicines for Malaria Venture (MMV): A product development partnership funding the discovery, development and delivery of new antimalarial medicines. Comparable to IHI in operating as a PPP that channels public and industry funding into collaborative drug R&D projects.
• Foundation for the National Institutes of Health (FNIH): A US not-for-profit that convenes NIH, industry, academia, and patient organizations to fund biomedical research. Highly comparable to IHI as a PPP mechanism that raises and deploys co-funding for health R&D projects.
• European & Developing Countries Clinical Trials Partnership (EDCTP): An EU-supported public-public partnership funding clinical trials in sub-Saharan Africa. Directly comparable as a European-led, multi-stakeholder health R&D funding instrument, though narrower in disease scope than IHI.
• Drugs for Neglected Diseases Initiative (DNDi): A not-for-profit R&D organization that develops new treatments for neglected diseases through PPPs. Shares IHI's model of convening public funders, industry, and academia to deliver health innovations that markets alone would not.

Regional players

• Biomedical Advanced Research and Development Authority (BARDA): The US government agency that funds advanced development of medical countermeasures. Comparable in operating as a public-private co-development funder for health innovation, but anchored to US rather than European priorities.

Broad incumbents

• Bill & Melinda Gates Foundation: The largest philanthropic health R&D funder globally, with multi-billion-dollar commitments to global health. Comparable in scale and PPP-style grantmaking, but with much broader thematic scope and global geographic reach than IHI.
• National Institutes of Health (NIH): The US federal agency for biomedical and public health research. Operates at vastly larger scale than IHI, but shares the model of being a public anchor funder that convenes academic and industry researchers around health priorities.

Others

• European Investment Fund: The EU's specialist vehicle for providing financing to SMEs in health and life sciences. Adjacent to IHI as a complementary EU institution mobilizing public capital into European health innovation, though oriented toward financial rather than research funding.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/IMI_JU
• LinkedInlinkedin.com/company/Innovative-Medicines-Initiative-1126077

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innovative Medicines Initiative